Five Prime Therapeutics Inc

Five Prime Therapeutics — Corporate Update (November 2017)

14 slides from Five Prime Therapeutics's corporate update, Nov 8, 2017

  1. Slide 1: Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO

    Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO® and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements Disclaimer

    This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are

  3. Slide 3: Key Takeaways Regarding Cabiralizumab/Opdivo Combination in Pancreatic Cancer

    Durable clinical benefit in 5 of 31 patients in pancreatic cancer Including 3 independently confirmed responses in heavily pre-treated patients without microsatellite-instability (MSI) Responses associated with significant reduction in tumor marker CA19-9 Historically, pancreatic cancer without MSI

  4. Slide 4: Pancreatic Cancer in 2017

    4th most common cause of death due to cancer in the US (n ≈ 43,090) Higher than breast cancer (40,600) or prostate cancer (26,700)1 Most patients with pancreatic cancer are diagnosed at an advanced stage All stages have poor prognosis; even the earliest stage < 1/3 alive at 5 years In advanced stage

  5. Slide 5: No reported durable monotherapy responses in pancreatic cancer without MSI

    There are no reported durable monotherapy responses in pancreatic cancer without MSI: Anti-PD-1 Anti-CTLA4 Anti-PD1 monotherapy is ineffective in pancreatic cancer except in the <1-2% of patients who have microsatellite instability-high (MSI)2 Onivyde® (liposomal irinotecan) is the most recently FDA

  6. Slide 6: Rationale for Targeting CSF1-R-Dependent TAMs in Pancreatic Cancer

    Human pancreatic cancer cells and surrounding stroma induce CSF1R-dependent macrophages to a pro-tumor phenotype (Tumor Associated Macrophages) Tumor Associated Macrophages (TAMs) Promote a fibrotic tumor microenvironment, cancer cell survival and migration, and cancer cell resistance to chemotherap

  7. Slide 7: TAM Infiltration is Associated with Poor Prognosis in Pancreatic Cancer

    TAM Infiltration is Associated with Poor Prognosis in Pancreatic Cancer © 2017 Five Prime Therapeutics, Inc. All Rights Reserved Kurahara et al., J Surgical Res 2011 Zhu et al., Cancer Research 2014 Pancreatic cancer with a high number of TAMs (identified by CSF1R-dependent gene signature; CD68, MRC

  8. Slide 8: CSF-1R Blockade Acts Synergistically with Anti-PD-1 and Chemotherapy

    CSF-1R Blockade Acts Synergistically with Anti-PD-1 and Chemotherapy by Reprograming the Tumor Microenvironment Five Prime Data ORTHOTOPIC PANCREATIC CANCER MODEL + gemcitabine IgG Anti-PD1 Combo p=0.0001 p=0.03 0.0 0.5 1.0 1.5 2.0 Tumor Weight (mean g± SEM) Anti-CSF1R (FPA008) Anti-CSF1R (FPA008) ©

  9. Slide 9: Rationale for Combination Therapy: TAMs and Checkpoints Inhibit T Cell-Mediated Killing

    CD8 T Cell Tumor Cell PD-1 PD-L1 TAM CSF-1R PD-L1/PD-1 suppresses T cells TAMs produce factors that inhibit T cells © 2017 Five Prime Therapeutics, Inc. All Rights Reserved Rationale for Combination Therapy: TAMs and Checkpoints Inhibit T Cell-Mediated Killing Through Different Mechanisms

  10. Slide 10: Cabiralizumab/OPDIVO Combination Trial in Multiple Tumor Settings

    Cabiralizumab/OPDIVO® Combination Trial in Multiple Tumor Settings © 2017 Five Prime Therapeutics, Inc. All Rights Reserved PHASE 1b Cabiralizumab + OPDIVO ® Study Objectives Cabiralizumab Monotherapy N ~280 patients Safety Objective response rate and duration Survival Baseline and on-treatment biop

  11. Slide 11: Cabiralizumab +/- Nivolumab Demonstrates a Tolerable Safety Profile

    Cabiralizumab +/- Nivolumab Demonstrates a Tolerable Safety Profile © 2017 Five Prime Therapeutics, Inc. All Rights Reserved *Includes pneumonitis, respiratory distress and acute respiratory distress

  12. Slide 12: Deep and Durable Responses Observed with Significant Reduction in CA19-9

    Deep and Durable Responses Observed Accompanied by Significant Reduction in Pancreatic Tumor Marker CA19-9 © 2017 Five Prime Therapeutics, Inc. All Rights Reserved

  13. Slide 13: Conclusions

    Durable clinical benefit in 5 of 31 patients in pancreatic cancer Including 3 independently confirmed responses in heavily pre-treated patients without microsatellite-instability (MSI) Responses associated with significant reduction in tumor marker CA19-9 Historically, pancreatic cancer without MSI

  14. Slide 14: Thank You

    NASDAQ:FPRX Thank You www.fiveprime.com

Five Prime Therapeutics — Corporate Update (November 2017) on 6ix